Concurrent chemotherapy and immunotherapy

Details Concurrent chemotherapy and immunotherapy Concurrent chemotherapy and immunotherapy

A - Human Necessities

61

K

A61K 39/00 (2006.01)

Patent

CA 2628282

The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, hi fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.

Selon l~invention, l~administration simultanée de chimiothérapie et d~immunothérapie était jusqu~à présent contre-indiquée par peur que la lymphopénie induite ne diminue l~efficacité thérapeutique de l~immunothérapie. L~efficacité chimiothérapeutique du témozolomide a été démontrée chez des patients atteints de gliomes malins, et priver de cet agent les patients atteints de glioblastome (GBM) pour pouvoir les traiter par immunothérapie est sujet à controverse. La présente invention démontre, à l~encontre des théories établies, qu~une chimiothérapie et une immunothérapie peuvent être administrées simultanément sans effet négatif sur l~immunothérapie. Au contraire, la lymphopénie induite par le témozolomide peut en réalité agir en synergie avec un vaccin peptidique.

Affiliated with

Also associated with

Rating

Concurrent chemotherapy and immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Concurrent chemotherapy and immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Concurrent chemotherapy and immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1566457